General Partner, Hatteras Venture Partners
Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. Bob also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is a board member of Novan, Inc., and of HBM Healthcare Investments. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation. In 2013, he received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. Bob obtained his B.S. in Business Administration from Eastern Illinois University.